Eli Lilly and Company CEDEAR (LLYD)
BCBA
22.24
+0.48 (+2.21%)
Closed
Oct 7, 2026
Day's Range
22.0222.50
52 wk Range
12.7023.94
Financial Statements - LLYD - Eli Lilly and Company CEDEAR
Revenue
276.47K
Net Income
-22.44M▲ 26.1%Net Margin -8117.8%
EBITDA
-9.20M▲ 53.4%
Free Cash Flow
-7.97M▲ 23.7%
Income Statement
| Period Ending | 2022-04-30 | 2021-04-30 | 2020-04-30 |
|---|---|---|---|
| Sales | 276.47K | 0 | 0 |
| Cost of Goods | 186.78K | - | - |
| Gross Profit | 89.69K | - | - |
 Operating Expense | - | - | - |
| Operating Income | -9.81M | -24.34M | -41.12K |
| Non-Operating Interest | - | - | - |
| Other Income Expense | -12.59M | -6.01M | - |
| Pre Tax Income | -22.44M | -30.38M | -40.57K |
| Income Tax | - | - | - |
| Net Income | -22.44M | -30.38M | -40.57K |
| EPS Basic | - | -15.6 | -0.018176 |
| EPS Diluted | - | -15.6 | -0.018176 |
| Basic Shares Outstanding | - | 1.96M | 2.23M |
| Diluted Shares Outstanding | - | 1.96M | 2.23M |
| Ebit | - | - | - |
| Ebitda | -9.20M | -19.74M | -40.57K |
| Net Income Continuous Operations | -22.44M | -30.38M | -40.57K |
| Minority Interests | - | - | - |
| Preferred Stock Dividends | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
